A Phase I, Open, Multiple Dose, Dose Escalation And Expansion Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kn035 (Anti-Pd-L1 Antibody) Administered In Subcutaneous Injection As A Single Agent To Chinese Subjects With Advanced Solid Tumors.